

ALZ-801

Chemical Properties


CAS No. : 1034190-08-3

Formula: C₈H₁₈N₂O₄S

Molecular Weight: 238.3

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	ALZ-801 is an orally available, valine-conjugated prodrug of tramiprosate. ALZ-801 is an advanced and markedly improved candidate for the treatment of Alzheimer's disease. ALZ-801 is a potent and orally available small-molecule β -amyloid ($A\beta$) anti-oligomer and aggregation inhibitor, a valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound.
Targets(IC50)	Beta Amyloid
In vivo	The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice[1]. ALZ-801 (oral administration; 172 mg/kg; single dose) shows average AUCt values of 58,758 and 5841 ng/mL.h in plasma and brain, respectively.

Solubility Information

Solubility	DMSO: < 1 mg/mL (insoluble) H ₂ O: 130 mg/mL (545.53 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1964 mL	20.982 mL	41.9639 mL
5 mM	0.8393 mL	4.1964 mL	8.3928 mL
10 mM	0.4196 mL	2.0982 mL	4.1964 mL
50 mM	0.0839 mL	0.4196 mL	0.8393 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. *CNS Drugs*. 2018; 32(9): 849-861.

Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. *Clin Pharmacokinet*. 2018 Mar;57(3):315-333.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481